Orexo's latest in-vivo study reveals promising results for OX390, a potential treatment for opioid overdoses linked to certain dangerous substances. This marks a pivotal step in addressing public health challenges.

Orexo has reported promising in-vivo study outcomes for OX390, an emergency treatment for xylazine and medetomidine overdoses, demonstrating rapid nasal absorption of atipamezole.

Orexo AB has reached a non-binding agreement with the US Department of Justice to settle an ongoing investigation, paving the way for future developments.

Join Orexo on March 24, 2026, for their R&D Day, where they will present strategic insights and evolving drug delivery technologies.

Orexo AB proudly invites stakeholders to its R&D Day on March 24, 2026, in Stockholm, focusing on innovative strategies and future developments.

Orexo AB has announced significant changes to its organizational structure and leadership team to sharpen its focus on product development and meet market demands.

Swedish pharmaceutical company Orexo announces a major organizational change. This restructuring aims to boost its focus on new product development and enhancing existing technologies.

Orexo's groundbreaking AmorphOX technology shows promise in developing intranasal GLP-1 medications, enhancing delivery methods and patient adherence.

Orexo's latest AmorphOX technology offers promising advancements for intranasal GLP-1 medications, enhancing bioavailability and patient adherence.

Orexo announces its participation at the 2025 EAACI Congress, showcasing groundbreaking findings for OX640, a nasal treatment for severe allergic reactions.

Orexo has announced significant success in developing a new intranasal vaccine utilizing its innovative AmorphOX technology, showcasing strong immune responses.

Orexo announces promising in-vivo results from a novel intranasal vaccine developed using AmorphOX technology, enhancing pandemic response strategies.

Orexo has announced positive results from a clinical study of OX640, a nasal medication aimed at treating allergic reactions, promising rapid effectiveness.

Orexo's recent clinical trial for its nasal medication OX640 has shown encouraging results, indicating rapid absorption and effectiveness for allergy treatments.

Orexo has partnered with Abera to create nasal powder vaccines utilizing AmorphOX technology, aiming to enhance vaccine effectiveness and stability.

In a significant move, Orexo collaborates with Abera to harness the AmorphOX technology for creating nasal powder vaccines, targeting pandemic preparedness.

OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology EAACI is a leading global association devoted to allergic and immunology diseases Orexo´s advisor Dr....

OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology EAACI is a leading global association devoted to allergic and immunology diseases Orexo´s advisor Dr....

The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine…

The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine…

The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). The collaboration is in line with Orexo’s …